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Since the early 1980s, the implantable intrathecal drug pump (ITDP) has been used increasingly to manage chronic 
pain. Prior to making a decision to implant an ITDP, trial administration of the intrathecal (IT) drug should be 
performed to estimate the effective dose for a starting set of implantable ITDPs. There is no standard method of trial 
IT drug administration, though. Therefore, this paper reports 20 cases of IT morphine trial with single and repetitive 
injections until the appropriate dose was attained with respect to analgesia and its side effects. The trial procedure 
was performed with daily sequential IT injections using morphine and 0.3% mepivacaine. Twelve out of the total of 
20 patients had positive responses. Thus, it is inferred that daily sequential IT morphine injections combined with a 
placebo injection as a trial ITDP would be useful in evaluating the effectiveness and adverse effects of IT morphine 
infusion with clinically insignificant side effects. (Korean J Anesthesiol 2011; 60: 138-141)
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    The prevalence of moderate to severe chronic non-cancer 
pain in the general population has been reported to be 9-19% 
[1]. The most common condition of intractable chronic pain 
is neuropathic in nature, including complex regional pain 
syndrome (CRPS), post-laminectomy pain syndrome (PLPS, 
which is persistent pain following back surgery), and pain 
caused by nervous system injury or dysfunction. Treatments 
for chronic pain should employ a multidisciplinary approach. 
Although all modalities for the management of chronic pain 
have been tried, some chronic pain patients are still suffering 
from intractable pain. Currently, neuromodulation therapies 
such as stimulation of the spinal cord, thalamus, or motor 
cortex, and intrathecal (IT) drug infusion could be final options 
to managing intractable chronic pain [2,3].139 www.ekja.org
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    For modern pain medicine, opioid receptors in the nervous 
tissues were first found in 1973 [4]. The first clinical use of IT 
morphine to treat intractable cancer pain was reported by Wang 
et al. in 1979 [5]. In addition to that, continuous IT drug infusion 
using an implantable pump was introduced in a chronic cancer 
pain patient in 1981 [6]. Since the early 1980s, the implantable 
IT pump has been used increasingly to manage chronic pain, as 
the technology for the device has also been developed.
    IT analgesia could have benefits for patients with intractable 
pain after they have undergone all the treatment modalities 
of or taken a high dose of opioid therapy. Successful use of 
IT implantable devices should be preceded, however, by the 
determination of the appropriate analgesic dosefor. Clinical 
practitioners have used different methods for this, such as 
intrathecal or epidural bolus injection, and intrathecal or 
epidural indwelling catheter placement. So far, however, there 
is still no standard method of trial IT drug administration. 
Therefore, this paper reports 20 cases of IT morphine trial with 
single and repetitive injections until the appropriate dose was 
attained with respect to analgesia and its side effects. 
Case Report
    A total of 20 patients with intractable chronic pain who had 
trial intrathecal morphine injections between March and 
August 2009 at the pain clinic of the authors’ university hospital 
were included in this study. All of them had severe chronic pain 
with non-malignant refractory to conservative management, 
such as oral or parenteral opioids and multiple therapies. 
    The participants’ informed consent was obtained after the 
nature of this study was explained to them. Then they were 
placed in a lateral decubitus position on a table, and their 
skin was prepared for needle insertion using an iodine-based 
antiseptic solution. A 25-gauge 10 cm spinal needle (Hakko
Ⓡ, 
Hakko, Japan) was inserted in the L3-4 or L4-5 interspinous 
space and advanced to obtain a spontaneous flow of cerebro-
spinal fluid (CSF). 
    After confirming the CSF free flow through a needle, a mixed 
solution of morphine sulfate (1 mg/ml/ampule: BCWorld 
Pharmacy Co., Ltd., Seoul, Korea) and 0.3% mepivacaine 
(Mevan
Ⓡ, 20 mg/ml/vial: HANLIM, Korea) was administered 
intrathecally. These two drugs do not contain preservatives. 
The morphine dose was measured with a 1 ml syringe and 
mixed with 2 ml of 0.3% mepivacaine in a 5 ml syringe. Only 
in the case of the use of 0.075 mg of morphine was morphine 
diluted first with 0.3% mepivacaine. For example, 1 ml (1 mg) 
of morphine and 1 ml of 0.3% mepivacaine were mixed in a 5 
ml syringe, and then 0.15 ml (0.075 mg) of the mixed solution 
was withdrawn to formulate the injection solution with 2 
ml of 0.3% mepivacaine. The total volumes of the injection 
solution were 2.15 ml (morphine, 0.075 mg and 0.15 mg), 2.3 
ml (morphine, 0.3 mg), 2.5 ml (morphine, 0.5 mg), and 2.7 ml 
(morphine, 0.7 mg), depending on the morphine doses. The 
morphine dose was determined based on the amount of oral 
opioids and the patient’s age. If the patient was below 65 years 
old or consumed opioids with an equivalent dose of more than 
90 mg of morphine, 0.3 mg of morphine was used for the initial 
dose. If the patient was more than 65 years old or consumed 
opioids with an equivalent dose of less than 90 mg of morphine, 
0.15 mg of morphine was administered for the initial dose. If 
the patient had a poor clinical condition, the first trial injection 
was made with 0.075 mg of morphine. A positive response was 
Fig. 1.  The study protocol. 0.075 mg 
(0.075 ml) of morphine was mixed with 
0.075 ml of 0.3% mepivacaine first, and 
2.15 ml of mixed solution containing 
of 0.075 mg of morphine with 2.075 
ml of 0.3% mepivacaine was used for 
intrathecal test dose.140 www.ekja.org
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defined as at least 50% pain relief in 8 hours after the intrathecal 
administration of the trial morphine. The study protocol is 
summarized in Fig. 1.
    If the patient had a positive response but an uncomfortable 
side effect, the first dose of morphine was used for the second 
trial injection to evaluate the possibility of the degradation of 
the side effect. If a patient had a negative response with 0.075 or 
0.15 mg of initial morphine, a double dose of initial morphine 
was administered to see if the positive response would be 
induced. If a patient had a negative response with 0.3 mg of 
morphine, 0.2 mg of morphine was added to the previous 
injection on the next day. If a patient had a positive response 
to the trial intrathecal injection at any dose of morphine, 2 ml 
of normal saline was administered intrathecally to rule out the 
placebo effect on the next day. 
    The pain relief and side effects were evaluated with a num-
erical rating scale (NRS) of 0 to 10 (where 0 means nothing and 
10 represents the worst condition imaginable) at each injection. 
    A total of 20 patients underwent trial IT morphine injections. 
Fourteen patients were male and six were female. The patients’ 
clinical characteristics and the results of this study are 
summarized in Table 1 and 2, respectively. The mean age of the 
study patients was 44 (16-78) years. The average number of 
trial injections was 3. 
    Twelve (60%) of the total number of patients had a positive 
response. The average pain relief was described with NRS 2.8 
from 8 of the subjects. Six of the subjects underwent implan-
tation of an intrathecal drug pump (ITDP). One of the 12 subjects, 
a 61-year-old man with post-laminectomy pain syndrome 
(PLPS), did not receive an implantation of ITDP because of the 
morphine-induced side effect of urinary retention. The high 
cost of ITDP implantation was cited most often as the reason for 
rejecting the performance of the procedure. 
    Three (15%) of the patients did not experience side effects. 
Seventeen patients experienced side effects, the most common 
of which were itching (11/20), urinary retention (9/20), nausea 
(4/20), dizziness (2/20), and postdural puncture headache 
(PDPH) (1/20). Twelve of 17 patients with side effects reported 
mild degrees of degradation with repetitive injections. Five 
of the eight non-responders experienced moderate to severe 
degrees of side effects. 
Table 1. Demographic Data of the Study Patients
Number
Age (range)
Sex (male/female)
Diagnosis
    Postlaminectomy syndrome - lumabar
    Postlaminectomy syndrome - cervical
    CRPS
    PHN
    Central pain
    Others
20
44.1 (16-78)
14/6
5
3
4
1
3
4
PLPS-L: Post-laminectomy syndrome – lumabar, PLPS-C: Post-
lami  nectomy syndrome – cervical, CRPS: complex regional pain 
syndrome,  PHN: postherpetic neurallgia. 
Table 2. Summary of Patient Characteristics and Outcome of Intrathecal Morphine Infusion as a Diagnostic Test
No. Diagnosis Pre NRS Post NRS S (mg) F (mg)
Number  
of test
S/Ex
Pump
implatation
Cause of
 refusal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Central pain
Central pain
Central pain
CRPS
CRPS
CRPS
CRPS
Erythromelalgia
PLPS-L
PLPS-L
PLPS-L
PLPS-L
PLPS-L
PLPS-C
PLPS-C
PLPS-C
MPS
Functional abdominal pain
Peripheral neuropathy
PHN
9
5
10
9
8
7
6
8
8
8
6
7
7
7
8
4
9
9
6
7
9
2
0
4
4
3
6
4
4
4
5
3
2
3
7
3
9
8
2
7
0.3
0.3
0.15
0.3
0.3
0.3
0.15
0.075
0.15
0.15
0.15
0.15
0.3
0.3
0.075
0.15
0.3
0.15
0.075
0.15
0.3
0.5
0.3
0.3
0.3
0.5
0.3
0.15
0.15
0.5
0.3
0.15
0.7
0.5
0.075
0.15
0.5
0.15
0.15
0.5
3
6
3
1
3
8
2
4
3
3
2
5
4
3
2
1
2
3
3
3
DU, I, N
I
D
DU, I
I
DU, I
DU, I
None
I
I
DU
DU
None
N
N/V, I
DU, I
I, PDPH
N, D, I
DU
None
n
n
y
n
y
y
n
y
n
y
n
n
y
n
n
n
n
n
n
n
NE
Other
.
Change to SCS
.
.
S/E
.
Cost
.
S/E
S/E
.
Cost
NE, S/E
S/E
NE
NE, S/E
Cost
NE
S: starting dose, F: final dose, No: number of test, DU: dysuria, I: itching, N: nausea, V: vomiting, D: dizziness, S/E: side effect, NE: no 
effect, y: yes, n: no.141 www.ekja.org
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Discussion
    IT use of opioids has been growing with the development of 
the implantable ITDP for either malignant or non-malignant 
chronic pain, since opioid receptors in the nervous system were 
found in the late 1970s [6,7]. In Korea, the implantable ITDP 
was introduced in 2007, and a gradually increasing number 
of implantable ITDPs has been used to manage intractable 
chronic pain [8]. 
    In clinical practice, there are many causes of prolonged pain, 
as, for example, PLPS, CRPS, central pain, axial spinal pain with 
a non-specific origin, peripheral neuropathy, peripheral and 
central neuropathic pain caused by brachial plexitis, spinal cord 
injury etc., and failed spinal cord stimulation (SCS) therapy. 
In this study, the most common cause of chronic pain was 
PLPS, followed by CRPS. Although this study did not involve 
a randomized controlled trial, CRPS and PLPS patients had 
considerably good responses to IT morphine infusion; 75% (3/4) 
of the CRPS patients and 63% (5/8) of the PLPS patients had 
positive responses, among whom two of the four CRPS patients 
and two of the eight PLPS patients chose implantation of an 
ITDP. 
    Most clinical practitioners’ concerns about ITDP using 
morphine must be how much morphine would best relieve pain 
without side effects. It is important to estimate the side effects of 
IT morphine before deciding to perform the ITDP implantation. 
There is no standard method, however, of determining the 
proper dose of IT morphine before implantation of ITDP 
with morphine. So far, trial IT morphine injection has been 
performed either via intrathecal or epidural bolus injection 
or via continuous inthrathecal or epidural infusion of 
an indwelling catheter. Unfortunately, four types of trial 
administration of morphine have a strong limitation as to their 
inability to prognosticate the long-term outcome. About 59.8% 
of trial IT injections have been performed through the epidural 
route, but epidural medication could not estimate the direct IT 
drug effect, even though it does not need dural puncture [7]. 
    Although trial injection through the IT route could more likely 
develop meningitis or PDPH via penetration of the dura, it is 
more likely to produce a side effect similar to that of morphine 
released from a real ITDP [9]. In this study, a 25-gauge 10 cm 
spinal needle (Hakko
Ⓡ, Hakko, Japan) was used, and one 
patient who had PDPH was not clinically affected and his 
condition was resolved spontaneously without any treatment. 
Using an IT-indwelling catheter for continuous infusion would 
have conditions most similar to those of ITDP infusion, but 
infection and CSF leakage could be causes for greater concern. 
Furthermore, there is currently no commercial IT-indwelling 
catheter in Korea. In this study, the patients underwent 
daily sequential IT single-shot injections to access a direct 
subarachnoid space for administration of the drug and to adjust 
the dose of morphine more properly. Generally, morphine has 
water-soluble pharmacokinetics, and the onset of its action 
occurs in approximately 30 minutes to 1 hour, with an effect 
that lasts as long as 18-24 hours [10]. The treatment goal in 
this study was at least 50% pain relief, which was the end point 
of the trial IT injection. Furthermore, in this study, the same 
amount of normal saline was injected intrathecally if the patient 
reported a positive response, which excluded the placebo effect. 
    In conclusion, the results of this study show that daily 
sequential IT morphine injection combined with placebo 
injection as a trial ITDP would be useful in evaluating the 
effectiveness and adverse effects of IT morphine infusion 
without clinically significant complications. In addition, daily 
incremental doses of 0.2 mg of morphine could be an easy and 
safe way to determine the appropriate dose of morphine for the 
initiation of the ITDP implantation. 
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